Reports
Sale
Global Adalimumab Drugs Market Size, Share, Trends, Forecast: By Indication: Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Chronic Plaque Psoriasis, Crohn's Disease, Ulcerative Colitis, Others; By Type; By Route of Administration; By Age Group; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032
Global Adalimumab Drugs Market Outlook
The global adalimumab drugs market size is driven by rising emphasis on developing targeted therapies across the globe. The market is expected to grow at a CAGR of 5.1% during the forecast period of 2024-2032.
Global Adalimumab Drugs Market Overview
Adalimumab is a generic name for Humira medicine and its biosimilars. It is a TNF alpha inhibitor used to reduce inflammation and pain, along with skin associated symptoms in chronic autoimmune conditions, such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), plaque psoriasis (Ps), Crohn's disease, ankylosing spondylitis, uveitis, ulcerative colitis, and juvenile idiopathic arthritis. The adalimumab drugs market demand is primarily driven by the increasing prevalence of autoimmune diseases.
Rheumatoid arthritis has a prevalence of 40 per 100,000 people in the United States and Northern European countries. Psoriatic arthritis is estimated to have a prevalence of 0.05 to 0.25% in the general population whereas the psoriasis affected patients are more likely to develop the condition (6% to 41%). The prevalence rate of ulcerative colitis was estimated to be around 5 million in 2023. Lifestyle changes such as elevated stress levels, unhealthy dietary habits and environmental factors have all contributed to the higher incidence.
Biosimilars Expected to Lead the Adalimumab Drugs Market Share
Owing to the easy availability and high efficacy, adalimumab drugs has garnered wide popularity in recent years. With rising technical advancements in medical technology and a heightened focus on personalised medicines, the production, and regulatory approvals for biosimilars has increased.
In July 2023, Boehringer Ingelheim’s interchangeable adalimumab biosimilar, called Cyltzo received FDA approval and was made commercially available in the United States market. The approval was based on the promising results showcased in Phase III randomized VOLTAIRE-X comparative clinical trial. The increasing approvals to offer improved and affordable solutions to the patients is anticipated to be a major factor boosting the adalimumab drugs market growth in the forecast period.
In March 2023, Sandoz , a pioneer in generic pharmaceuticals and biosimilars received FDA approval for citrate-free high-concentration formulation (HCF) of its biosimilar Hyrimoz® (adalimumab-adaz) injection. The approval was based on Phase I pharmacokinetics (PK) study that compared adalimumab 50 mg/mL to the citrate-free 100 mg/mL. Hyrimoz® marks the first launch of a Sandoz biosimilar in the United States market.
Collaborative Efforts with Online Pharmacies to Make the Drug Available at an Affordable Price
To offer better accessibility and affordability of drugs to patients, there is a rising focus on making biosimilars available in online pharmacies. In June 2023, Coherus Biosciences partnered with Mark Cuban Cost Plus Drug Company’s online pharmacy chain to offer adalimumab’s biosimilar, YUSIMRY (adalimumab-aqvh) at a pocket-friendly price. YUSIMRY is enabled with art autoinjector presentation and integrates the non-stinging, citrate free formulation and a 29-gauge needle by Coherus Biosciences. Understanding the rising popularity and preference of at-home services, this partnership is expected to open a new realm of convenience for patients, fuelling a rise in the adalimumab drugs market size significantly.
Global Adalimumab Drugs Market Segmentation
Market Breakup by Indication
- Rheumatoid Arthritis
- Psoriatic Arthritis
- Ankylosing Spondylitis
- Chronic Plaque Psoriasis
- Crohn's Disease
- Ulcerative Colitis
- Others
Market Breakup by Type
- Biologics
- Biosimilars
Market Breakup by Route of Administration
- Oral
- Parenteral
- Others
Market Breakup by Age Group
- Pediatric
- Adult
- Geriatric
Market Breakup by Distribution Channel
- Hospitals
- Specialty Clinics
- Homecare
- Others
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Global Adalimumab Drugs Market Regional Analysis
North America, particularly the United States, is projected to lead the global market. The market size can be accredited to the presence of prominent pharmaceutical companies, continuously working on producing biosimilars along with proactive regulatory authorities such as the United States FDA for maintaining the quality of the drugs.
Owing to a substantial portion of the geriatric population in the region, Europe turns out to be another key market. The older population is more susceptible to develop diseases such as arthritis, hence the government is taking multiple initiatives to promote effective treatment methods. The presence of influential academic and research institutions along with a well-structured research infrastructure also fuels market growth.
The Asia Pacific adalimumab drugs market value is poised to witness ample growth, accredited to rising improvements in the region’s healthcare infrastructure. Emerging economies such as India and South Korea are major centres of foreign investments. In addition, there is a trend of growing collaborations between private and public institutions to offer the best treatment outcomes to patients.
Global Adalimumab Drugs Market: Competitor Landscape
In January 2023, Amgen made AMJEVITA™ (their biosimilar to Humira) available in their United States market. The biosimilar was available at a price 55% lower than the standard Humira price, facilitating a better access to a wider section of the patients. In addition, it was available in prefilled syringe as well as autoinjector presentations to support dosing based on approved indications. This indicates a common market trend involving a greater number of companies working to develop biosimilars.
The key features of the adalimumab drugs market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- F. Hoffmann-La Roche Ltd.
- Mylan N.V.
- Teva Pharmaceutical Industries Ltd.
- Sanofi
- GlaxoSmithKline plc
- Novartis AG
- Pfizer Inc. (US)
- Biogen
- Fresenius Kabi AG
- Zydus Cadila
- Boehringer Ingelheim International GmbH
- Amgen Inc.
- AbbVie Inc.
- Abbott
- CELLTRION INC.
- Samsung Bioepis
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Indication |
|
| Breakup by Type |
|
| Breakup by Route of Administration |
|
| Breakup by Age Group |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Adalimumab Drugs Market Overview
3.1 Global Adalimumab Drugs Market Historical Value (2017-2023)
3.2 Global Adalimumab Drugs Market Forecast Value (2024-2032)
4 Global Adalimumab Drugs Market Landscape
4.1 Global Adalimumab Drugs Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Adalimumab Drugs Product Landscape
4.2.1 Analysis by Type
4.2.2 Analysis by Indications
4.2.3 Analysis by Route of Administration
5 Global Adalimumab Drugs Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Adalimumab Drugs Market Segmentation
6.1 Global Adalimumab Drugs Market by Indication
6.1.1 Market Overview
6.1.2 Rheumatoid Arthritis
6.1.3 Psoriatic Arthritis
6.1.4 Ankylosing Spondylitis
6.1.5 Chronic Plaque Psoriasis
6.1.6 Crohn's Disease
6.1.7 Ulcerative Colitis
6.1.8 Others
6.2 Global Adalimumab Drugs Market by Type
6.2.1 Market Overview
6.2.2 Biologics
6.2.3 Biosimilars
6.3 Global Adalimumab Drugs Market by Route of Administration
6.3.1 Market Overview
6.3.2 Oral
6.3.3 Parenteral
6.3.4 Others
6.4 Global Adalimumab Drugs Market by Age Group
6.4.1 Market Overview
6.4.2 Pediatric
6.4.3 Adult
6.4.4 Geriatric
6.5 Global Adalimumab Drugs Market by Distribution Channel
6.5.1 Market Overview
6.5.2 Hospitals
6.5.3 Specialty Clinics
6.5.4 Homecare
6.5.5 Others
6.6 Global Adalimumab Drugs Market by Region
6.6.1 Market Overview
6.6.2 North America
6.6.3 Europe
6.6.4 Asia Pacific
6.6.5 Latin America
6.6.6 Middle East and Africa
7 North America Adalimumab Drugs Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Adalimumab Drugs Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Adalimumab Drugs Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Adalimumab Drugs Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Adalimumab Drugs Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
16.1.5 Others
17 Supplier Landscape
17.1 F. Hoffmann-La Roche Ltd.
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 Mylan N.V.
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Teva Pharmaceutical Industries Ltd.
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Sanofi
17.4.1 Financial Analysis
17.4.2 Financial Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 GlaxoSmithKline plc
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Novartis AG
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 Pfizer Inc. (US)
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 Biogen
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Fresenius Kabi AG
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 Zydus Cadila
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 Boehringer Ingelheim International GmbH
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
17.12 Amgen Inc.
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.12.5 Certifications
17.13 AbbVie Inc.
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisitions
17.13.5 Certifications
17.14 Abbott
17.14.1 Financial Analysis
17.14.2 Product Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisitions
17.14.5 Certifications
17.15 CELLTRION INC.
17.15.1 Financial Analysis
17.15.2 Product Portfolio
17.15.3 Demographic Reach and Achievements
17.15.4 Mergers and Acquisitions
17.15.5 Certifications
17.16 Samsung Bioepis
17.16.1 Financial Analysis
17.16.2 Product Portfolio
17.16.3 Demographic Reach and Achievements
17.16.4 Mergers and Acquisitions
17.16.5 Certifications
18 Global Adalimumab Drugs Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market is anticipated to grow at a CAGR of 5.1% during the forecast period of 2024-2032.
The market demand is driven by the increasing incidence of autoimmune diseases and the high efficacy of adalimumab drugs in treating multiple diseases.
The current market trend revolves around the increasing number of FDA approvals for marketing adalimumab biosimilars in the market. In July 2023, Cyltezo’s interchangeable adalimumab biosimilar was launched in the United States market.
Based on age groups, the market is divided into pediatrics, adult, and geriatrics.
Major distribution channels include hospitals, speciality clinics, and homecare, among others.
The route of administration can be oral and parenteral, among others.
Biologics and biosimilars are common drugs available in the market.
It includes rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, chronic plaque psoriasis, Crohn's disease, and ulcerative colitis, among others.
The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America is currently leading the global market
Key players involved in the market are F. Hoffmann-La Roche Ltd., Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi, GlaxoSmithKline plc, Novartis AG, Pfizer Inc. (US), Biogen, Fresenius Kabi AG, Zydus Cadila, Boehringer Ingelheim International GmbH, Amgen Inc., AbbVie Inc., Abbott, CELLTRION INC. and Samsung Bioepis.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER